Biogen drops Alzheimer’s drug Aduhelm to focus on Leqembi, others
The Biogen headquarters in Cambridge, Massachusetts, on Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer’s drug Aduhelm to refocus the company’s efforts to treat the memory-robbing disease. The biotech company will focus on rolling out … Read more